Sylvia ter Meulen

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Christian U. Blank, Elisa A. Rozeman, Lorenzo F. Fanchi et al. · Nature Medicine · 2018 · 855 citations

Medicine, Immunology, Oncology +14

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · The Lancet Oncology · 2019 · 522 citations

Pharmacy, Oncology, Pharmacokinetics +16

High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a)

Viola Franke, Danique M.S. Berger, W. Martin C. Klop et al. · International Journal of Cancer · 2019 · 96 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Surgical wound complications after groin dissection in melanoma patients – A historical cohort study and risk factor analysis

Martijn M. Stuiver, E. Westerduin, Sylvia ter Meulen et al. · European Journal of Surgical Oncology · 2014 · 63 citations

Medicine, Oncology, Surgery +17

The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients—Results after 1 Year

Samantha Damude, Josette E. H. M. Hoekstra‐Weebers, Anne Brecht Francken et al. · Annals of Surgical Oncology · 2016 · 50 citations · Full text

Medicine, Dermatology, Oncology +14